In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM)  by Ghazi, Islam M. et al.
In vivo efficacy of humanized






Islam M. Ghazi a, Jared L. Crandon a, Emil P. Lesho b, Patrick McGann b,
David P. Nicolau a,c,*
aCenter for Anti-infective Research and Development, Hartford Hospital, Hartford, CT, USA
bWalter Reed Army Institute of Research, Silver Spring, MD, USA
cDivision of Infectious Diseases, Hartford Hospital, Hartford, CT, USA
*Corresponding author at: Center for Anti-infective Research and Development, Hartford Hospital, 80 Seymour
Street, Hartford, CT 06102, USA.
E-mail address: david.nicolau@hhchealth.org (D.P. Nicolau).
Abstract
Introduction:We aimed to describe the in vivo efficacy of meropenem, in addition
to cefepime and levofloxacin as comparators against VIM-producing Pseudomonas
aeruginosa and compare the findings to our previous observations with
Enterobacteriaceae.
Methods: Eight clinical P. aeruginosa isolates with meropenem MICs from 4 to
512 mg/L were studied in a murine neutropenic thigh infection model. Animals were
treated with doses of the antibiotics to simulate the human exposure of meropenem
2 g q8 h 30-min infusion, cefepime 2 g q8 h 30-min infusion and levofloxacin







Heliyon 2 (2016) e00121
http://dx.doi.org/10.1016/j.heliyon.2016.e00121
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
calculated as the change in thigh bacterial density (log10 CFU) relative to the starting
inoculum (0 h).
Results: As expected, levofloxacin was ineffective against all isolates due to their
resistant phenotype (8 to>64 mg/L). Cefepime also showed minimal activity
against all isolates consistent with its failure to achieve pharmacodynamic target
exposures due to high MICs of 32 to>512 mg/L. In the presence of low MICs (4 to
16 mg/L), the fT> MIC of meropenem was sufficiently high to result in CFU
reductions. However, conflicting activity was noted for isolates with MICs = 128
mg/L that possessed the same enzymatic profile, suggesting that other mechanisms
of resistance are responsible for driving CFU outcomes. No activity was noted for
organisms with a meropenem MIC = 512 mg/L.
Conclusion: Unlike previous observations with MBL-producing Enterobacter-
iaceae that showed discordance between in vitro resistance and in vivo efficacy in
the murine infection model, we found that the efficacy of humanized cefepime and




Infections caused by multi-drug resistant (MDR) pathogens, including Pseudomo-
nas aeruginosa are increasing globally. P. aeruginosa is often thought of as the
prototypic MDR organism as it is capable of developing resistance by utilizing
both non-enzymatic, such as modification of the outer membrane protein OprD,
and enzymatic processes, which include mutations in chromosomal genes or
transferable resistance determinants such as metallo-β-lactamases (MBLs) and
extended spectrum β-lactamases (ESBL) [1]. The spread of MBLs among P.
aeruginosa and Enterobacteriaceae has been rising in the recent years. Among the
clinically relevant MBL enzymes is VIM, which was first recovered in Italy in
1997 and manifested resistance to several β-lactam antibiotics, including imipenem
with a minimum inhibitory concentration (MIC) of>128 mg/L [2]. As a result of
these emerging resistance trends and the limited therapeutics options against these
MBLs, investigations assessing the clinical implications of resistance as defined by
the current in vitro criteria are required. To this end, previously conducted studies
suggest that for Enterobacteriaceae, humanized exposures of carbapenems retain
in vivo activity against two MBL-producers (NDM and VIM), despite resistant as
defined by in vitro MICs [3, 4]. In this study, we sought to compare and contrast
the effect of VIM production in Enterobacteriaceae and P. aeruginosa by
characterizing the efficacy of meropenem and comparators, levofloxacin and
cefepime, against VIM-producing P. aeruginosa.
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2. Methods
The ethical approval was obtained from Institutional Animal Care and Use
Committee before the start of the study. Commercially available levofloxacin
(Akorn Inc, Lake Forest, IL), meropenem (Hospira Inc, Lake Forest, IL) and
cefepime (Sagent, Schaumberg, IL) were acquired from the Hartford Hospital
Pharmacy Department (Hartford, CT) to be used during in vivo experimentation.
All antibiotics were reconstituted according the manufacturers’ recommendations
and further diluted to the required concentration using normal saline shortly before
the experiment.
A total of eight clinical P. aeruginosa isolates were tested (Table 1). All isolates
were frozen at −80 °C in double strength skim milk (Remel, Lenexa, KS) and
cultured twice consecutively on trypticase soy agar with 5% sheep blood (BD
Biosciences, Sparks, MD) and incubated at 35 °C for 18–24 hours prior to
experimentation. Levofloxacin, meropenem, and cefepime MICs were determined
using broth microdilution in accordance with Clinical Laboratory Standards
Institute (CLSI) methodology using standard analytical powder (Sigma-Aldrich,
St. Louis, MO) [5].
Table 1. List of the tested isolates with their respective genotypes and MICs.
Clinical isolates β-lactamases encoded MIC (mg/L)
LEV FEP MER
PSA 1550 VIM-1, OXA-10, OXA-50 32 64 4
PSA 1480 VIM-2, OXA-2, OXA-10, OXA-50, 64 32 16
PSA 1475 VIM-1, OXA-50, 8 >512 64
PSA 1465 VIM-1, OXA-50, >64 512 128
PSA 1478 VIM-1, OXA-50, >64 256 128
PSA 1466 VIM-2 OXA-4, OXA-50, >64 256 512
PSA 1476 VIM-1, OXA-50, 16 >512 512
PSA 1549 VIM-6, OXA-10, OXA-50 >64 256 512
PSA: P. aeruginosa.
LEV; levofloxacin, FEP; cefepime, MER; meropenem.
European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints:
Levofloxacin; susceptible ≤ 1 mg/L.
Cefepime; susceptible ≤ 8 mg/L.
Meropenem; susceptible ≤ 8 mg/L.
Clinical Laboratory Standards Institute (CLSI) breakpoints:
Levofloxacin; susceptible ≤ 2 mg/L.
Cefepime; susceptible ≤ 8 mg/L.
Meropenem; susceptible ≤ 4 mg/L.
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Whole genome sequencing was performed using an Illumina MiSeq desktop
sequencer at Walter Reed Army Institute of Research (Silver Spring, MD, USA),
as previously described [6, 7]. Multilocus sequence type profiles were determined
based on database maintained by the Institut Pasteur (Paris, France) and by NCBI
(Bethesda, MD, USA), respectively. The study was reviewed and approved by the
Institutional Animal Care and Use Committee at Hartford Hospital, Hartford, CT
and animals were kept in consistence with National Research Council’s
recommendations and given nutrition ad libitum. ICR mice with an average
weight of 22 g were obtained from Harlan Laboratories (Indianapolis, IN) and
utilized throughout. Neutropenia was induced with cyclophosphamide 150 mg/kg
and 100 mg/kg at 4 days and 1 day prior to inoculation, respectively. In addition,
uranyl nitrate 5 mg/kg was administered three days prior to inoculation to produce
a controlled degree of renal impairment. The study animals were inoculated in each
thigh with 0.1 ml of bacterial suspension containing 107 CFU/ml of the test isolate
in normal saline and antibiotic administration started 2 hours later. Humanized
doses of levofloxacin 500 mg q24 h designed to achieve an AUC of 42–53 mg.h/L
[8], meropenem 2 g q8 h as 30-min infusion [9] and cefepime 2 g q8 h as 30-min
infusion [10], as previously developed and validated by our group, were
administered as 0.2 ml subcutaneous injections to groups of three animals over
24 hours. The β-lactams regimens were designed to simulate the pharmacodynamic
profile observed in humans given these regimens (Table 2). As required to
optimize the use of animals in research, repeated PK studies were not done in our
current investigation because exposure profile validation was defined previously in
our laboratory on the same mice species. A group of three mice was harvested at
the beginning of dosing to serve as 0 hour controls and another group was given
0.2 ml subcutaneous normal saline as frequently as the most dosed antibiotic for
each isolate. At the end of 24-hour study period, treatment and control animals
Table 2. Expected free drug time above the minimum inhibitory concentration
(MIC) at different values of MIC for cefepime and meropenem.
fT> MIC(%)







Adapted from [9] and [10].
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were euthanized by CO2 exposure followed by cervical dislocation; thighs were
excised from sacrificed animals, homogenized in 5 ml of normal saline (mini bead-
beater, BioSpec Products, Bartlesville, OK), and serially diluted and plated on
trypticase soy agar with 5% sheep blood for counting of bacterial densities.
Efficacy was calculated as the change in bacterial density (log10 CFU) of
intervention groups compared with the 0 hour control group. To assure enzyme
production across experimentation, thigh homogenates from 0-hour and 24-hour
control animals, as well as, meropenem treated mice were plated on agar
containing meropenem concentrations equivalent to the MIC of the test strain.
3. Results
A list of study isolates along with their respective MIC and genotypes is shown in
Table 1. The growth (mean ± SD) of the 0h-control group was 5.00 ± 0.36 log10
CFU while that of 24h-control group was 8.52 ± 0.47. Levofloxacin (Fig. 1)
exhibited a lack of activity against all tested isolates as predicted based on the
[(Fig._1)TD$FIG]
Fig. 1. Efficacy of humanized levofloxacin 500 mg q24 h, cefepime 2 g q8 h 30-min. infusion and
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phenotypic profile of the test strains. Similarly, humanized cefepime had minimal
activity against the 8 isolates, consistent with the inability of this regimen to
achieve pharmacodynamic targets (Table 2). Conversely, meropenem was
predictably active against PSA1550 and PSA1480 as their MIC profiles resulted
in sufficiently high free drug exposures. Moreover, while the fT> MIC of
PSA1475 was reduced (5–18%), considerable efficacy was noted for this isolate.
Activity was also observed for PSA1478 (MIC = 128 mg/L, fT> MIC = 0–5%), on
the other hand there was no activity against PSA 1465 with the same MIC. No
activity was observed for the remaining 3 strains with MIC of 512 mg/L. All
isolates recovered from the mice after treatment showed growth on meropenem
containing plates, thus confirming the presence of enzyme mediated activity
throughout the in vivo exposure period.
4. Discussion
The acquisition of resistance by P. aeruginosa with reports of emerging metallo-
β-lactamases worldwide is a growing challenge in nosocomial infections and
efforts are needed to describe appropriate treatment options [11]. In the current in
vivo murine study employing humanized exposures, we found that the in vitroMIC
of VIM-producing P. aeruginosa was reflective of the in vivo activity of
levofloxacin, cefepime, and meropenem. These observations in P. aeruginosa were
unlike what we have previously demonstrated with Enterobacteriaceae [3, 4]. As
such, these current data suggest that for VIM-producing P. aeruginosa the
expected clinical efficacy of monotherapy will be governed by the achievement of
an optimized pharmacodynamic profile according to the principle driver (i.e., fT>
MIC, AUC/MIC) for the class of compounds under consideration.
While the concept of pharmacodynamic predictability among antimicrobials is
certainly not novel [12], previous studies by our group with carbapenemase-
producing Enterobacteriaceae have yielded varied results, particularly for the
β-lactams [3, 4, 13, 14]. Namely, while the activity of carbapenems and
cephalosporins were pharmacodynamically concordant against KPC-producing
strains, activity against MBL-producers (i.e., NDM or VIM), particularly for the
carbapenems, was observed in vivo, despite elevated in vitroMICs. While evidence
seems to suggest that MBLs have a diminished impact in vivo, the discordance
between observations against MBL-producing Enterobacteriaceae and P. aerugi-
nosa is hypothesized to be due to the myriad of other resistance mechanisms
present in P. aeruginosa, such as porin or efflux proteins [1]. This is reflected in
the current study by the observation that two isolates with the same MIC and
enzymatic resistance genotypes showed opposite killing patterns in vivo, thus the
overall contribution of the enzyme mediated resistance in vivo appears blunted in
the presence of alternative mechanisms.
Article No~e00121
6 http://dx.doi.org/10.1016/j.heliyon.2016.e00121
2405-8440/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
While we found the tested agents to be generally ineffective against resistant
strains, a previous study of a single VIM-producing P. aeruginosa in the rat
pneumonia model found that high doses of imipenem, cefepime, ceftazidime,
piperacillin/tazobactam and aztreonam (MICs were 128, 64, 256, 16 and 0.25 mg/
L, respectively) were effective in reducing bacterial loads in vivo despite in vitro
resistance [15]. While the use of human simulated exposures is mentioned by the
authors, the free-drug profile of their treatment regimens in blood and lung are not
provided; therefore direct comparisons between the two studies are difficult.
The available clinical data have repeatedly shown poor outcomes for patients
infected with multi-drug resistant P. aeruginosa producing VIM enzymes.
Assessments of appropriate empiric and definitive treatment are challenging given
that many of these organisms are resistant to almost all the antibiotics, except
colistin [16]. Moreover, in some cases these organisms are pan-drug resistant, with
combinations of colistin and β-lactams being reported as viable [17].
Unlike previous observations with MBL-producing Enterobacteriaceae, we found
that the MIC of the infecting VIM-producing P. aeruginosa predicted in vivo
efficacy of humanized cefepime and meropenem.
5. Conclusion
Given the high rates of resistance among these VIM-producing P. aeruginosa and
the resultant poor pharmacodynamics profiles treatment with monotherapy does
not appear to be a viable option for a large proportion of these strains and further
emphasizes the need for novel compounds targeted at these difficult pathogens.
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